MAXVAX Biotechnology
China - ChengduBiotechnology
Focus: MAXVAX Biotechnology is a vaccine-focused biotech company headquartered in Chengdu, China, specializing in recombinant vaccines for infectious diseases. Founded in 2006, the company is at Series C+ stage with a focused pipeline in viral vaccines.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Open Jobs
0
About MAXVAX Biotechnology
AI assessmentNot HiringNo open roles listed right now. Follow MAXVAX Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Low Dose Recombinant Herpes Zoster Vaccine
Herpes ZosterClinical Trials (1)
NCT05636436Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Phase 1Help build intelligence for MAXVAX Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.